All In Biotech

Investigational drug · Phase 3

Rovadicitinib

Also called: TQ05105

Not approved by FDA. In 5 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Chronic Graft Versus Host Disease, Myelofibrosis, Graft-versus-host Disease.

Phase 3

Last checked: Nov 20, 2026Latest source record: Aug 26, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

5

5 still active

All registered trials

3

Any phase or sponsor naming "Rovadicitinib"

First trial start

2021

Jun 25, 2021

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Rovadicitinib", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Chronic Graft Versus Host Disease
  • Myelofibrosis
  • Graft-versus-host Disease

Approved drugs for the same conditions: Myelofibrosis · Hematology and blood cancers

Largest trials

Live from ClinicalTrials.gov: studies naming "Rovadicitinib" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 11 on PubMed

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.